Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomy

Prostate

Volumn 48, Issue 3, 2001, Pages 136-143

  Shekarriz, Bijan ^a   Upadhyay, Jyoti ^a   Bianco Jr , Fernando J ^a   Tefilli, Marcos V ^a   Tiguert, Rabi ^a   Gheiler, Edward L ^a   Grignon, David J ^a   Pontes, J Edson ^a   Wood Jr , David P ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Organ confined disease; Pathological stage; Prognosis; Prostate cancer; Prostatic specific antigen; PSA; Radical prostatectomy; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE;

ADULT; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0034903701     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1092     Document Type: Article

References (29)

1. Detection of organ-confined prostate cancer is increased through prostate-specific antigen concentration
2. Prostate-specific antigen
3. National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening
4. Clinical stage BO or T1c prostate cancer: Nonpalpable disease identified by elevated serum prostate-specific antigen concentration
5. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
6. Serum PSA after anatomic radical prostatectomy. The John Hopkins experience after 10 years
7. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy
8. The definition and preoperative prediction of clinically insignificant prostate cancer
9. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
10. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma
11. Inadequacy of free prostate-specific antigen parameters in the prediction of pathologic extent of prostate cancer in Japanese men
12. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate antigen levels in radical prostatectomy patients
13. Evaluation the radical prostatectomy specimen
14. Prostate-specific antigen after anatomic radical retropubic prostatectomy
15. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
16. Ability of preoperative serum prostatic specific antigen value to predict pathological stage and tumor ploidy
17. Using PSA to screen for prostate cancer: The Washington university experience
18. Measurement of prostate specific antigen in serum as a screening test for prostate cancer
19. Prostate cancer detection in men with serum PSA concentrations of 2.6-4 ng/ml and benign prostate examination: Enhancement of specificity with free PSA measurement
20. Characteristics of screening detected prostate cancer in men 50-66 years old with 3-4 ng/ml prostate specific antigen
21. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges
22. Standard vs. age-specific prostatic specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis
23. Age-specific PSA reference ranges compared with the 4 ng/ml reference range in men with ≥ 60 years of age
24. Selection of optima prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves
25. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancer with a Hybritech prostate specific antigen of 4 to 10 ng/ml
26. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
27. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
28. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations